New & Noteworthy

Submit New & Noteworthy

February 2021

Increase in Copay Assistance for IG Therapy


Grifols announces an increase in copay assistance for Xembify (immune globulin subcutaneous human-klhw), a 20% subcutaneous immunoglobulin therapy for the treatment of patients 2 years of age and older with primary immunodeficiency disease. The increase doubles the amount provided from $5,000 to $10,000 per calendar year, and eligible patients may pay as little as $0 for Xembify treatment. In addition to the increase in the copay assistance program, Grifols offers Patient Assistance, a program for uninsured patients, through the Xembify Connexions patient support program.



Click here to view product detail on Findit.

Current Issue

Enter our Sweepstakes now for your chance to win the following prizes:

Just answer the following quick question for your chance to win:

To continue, you must either login or register: